In collaboration with Organizations pursuing anti-infective new drug discovery, invent proprietary new/novel antimicrobials, combinations, or repurpose to address the major challenge of AMR Antibiotics have transformed modern medicine. They are among our most transformative medicines which irrevocably increased our lifespan aka longevity by one to two decades in less than a century. They are essential for treating infectious diseases and enable vital therapies and procedures. However, despite this success, their continued use in the 21st century is imperilled by two orthogonal challenges. The first is that the microbes targeted by these drugs evolve resistance to them over time. The second is that antibiotic discovery and development are no longer cost-effective using traditional reimbursement models. Consequently, there are a dwindling number of companies and laboratories dedicated to delivering new antibiotics, resulting in an anaemic pipeline that threatens our control of infections. The future of antibiotics requires innovation in a field that has relied on highly traditional methods of discovery and development (Science 2022).